Alembic Pharmaceuticals

Alembic Pharmaceuticals, a company operating within the Pharmaceutical Preparation Manufacturing sector in India, has outlined ambitious climate commitments and provided emissions data for recent fiscal years.

For fiscal year 2025, Alembic Pharmaceuticals reported a total of approximately 761,179,000 kg CO2e. This figure is broken down into Scope 1 emissions of about 80,278,030 kg CO2e, Scope 2 emissions of approximately 77,965,980 kg CO2e, and substantial Scope 3 emissions amounting to about 602,934,950 kg CO2e.

In fiscal year 2024, the company's total emissions were approximately 824,980,000 kg CO2e. This comprised Scope 1 emissions of around 71,131,810 kg CO2e, Scope 2 emissions of approximately 67,544,140 kg CO2e, and Scope 3 emissions of about 686,303,840 kg CO2e.

For fiscal year 2023, Alembic Pharmaceuticals' total greenhouse gas emissions were approximately 761,438,000 kg CO2e. This included Scope 1 emissions of about 67,992,680 kg CO2e, Scope 2 emissions of approximately 83,482,350 kg CO2e, and Scope 3 emissions totalling about 609,962,840 kg CO2e.

Alembic Pharmaceuticals is committed to aligning its greenhouse gas (GHG) emissions reduction with a net-zero pathway by 2050. The company has set a target to achieve a 63% reduction in absolute Scope 1, 2, and 3 GHG emissions by FY2034, using FY2022 as the base year. Furthermore, they aim for a significant 90% reduction in absolute Scope 1, 2, and 3 GHG emissions by FY2050, also from a FY2022 base year. These targets are consistent with a 1.5°C warming scenario, indicating a strong commitment to science-based climate action.